17 Capital Partners LLC Acquires New Stake in Edwards Lifesciences Corporation $EW

17 Capital Partners LLC bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the fourth quarter, Holdings Channel.com reports. The fund bought 6,711 shares of the medical research company’s stock, valued at approximately $572,000.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. boosted its stake in Edwards Lifesciences by 0.5% during the third quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock worth $5,472,147,000 after buying an additional 365,581 shares during the last quarter. State Street Corp boosted its stake in Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares during the last quarter. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 4.9% during the third quarter. Wellington Management Group LLP now owns 20,804,416 shares of the medical research company’s stock worth $1,617,959,000 after buying an additional 977,933 shares during the last quarter. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter worth $803,686,000. Finally, Morgan Stanley lifted its stake in shares of Edwards Lifesciences by 12.4% in the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after purchasing an additional 804,942 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the topic of several recent analyst reports. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Mizuho set a $95.00 price target on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Evercore reiterated an “outperform” rating and issued a $93.00 price objective on shares of Edwards Lifesciences in a report on Friday, April 24th. TD Cowen reiterated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Robert W. Baird increased their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 81,038 shares of company stock worth $6,683,255 over the last ninety days. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Stock Down 0.9%

Shares of NYSE EW opened at $85.02 on Friday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $89.48. The business has a 50-day moving average price of $82.77 and a 200 day moving average price of $83.11. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.95 billion, a PE ratio of 45.22, a price-to-earnings-growth ratio of 2.13 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.